RSV Antibody for Babies (Nirsevimab) — Not a Vaccine

Nirsevimab is not a vaccine — it is a ready-made antibody injection that protects babies through their first RSV season. The CDC recommends 1 dose for babies under 8 months entering their first season whose mother did not receive the RSV vaccine in pregnancy.

Flu, COVID-19 & Respiratory — illustrative image
Flu, COVID-19 & Respiratory — illustrative image
Who it is forInfants under 8 months in their first RSV season; some toddlers 8–19 months at risk
Vaccine typeMonoclonal antibody (ready-made protection) — NOT a vaccine
Doses1 dose per RSV season
Schedule sourceCDC child schedule notes, 2025

RSV is the commonest cause of bronchiolitis and a leading cause of hospital admission in the first year of life. Babies cannot be given an RSV vaccine — none exists for infants — so protection comes in two other ways: vaccinating the mother in pregnancy so antibodies cross the placenta, or giving the baby a monoclonal antibody directly.

Nirsevimab (Beyfortus) is a laboratory-made antibody that lasts for months after a single injection. A second antibody product, clesrovimab, has also been licensed. Because the antibody is ready-made, protection starts immediately but fades over the season — unlike a vaccine, it teaches the baby's immune system nothing. Most babies need protection from only one route: either the mother's pregnancy vaccine or the baby's antibody, not both.

What this vaccine protects against

  • Severe RSV lower respiratory tract disease in the first months of life.
  • Bronchiolitis and RSV pneumonia requiring hospital care.
  • Severe RSV in high-risk toddlers entering their second season.

Who should get it, and when

Babies born during RSV season (October–March in most of the continental US) whose mother did not receive the RSV vaccine in this pregnancy — or received it less than 14 days before delivery, or whose status is unknown: 1 dose of nirsevimab within 1 week of birth, ideally during the birth hospital stay.

Babies born April–September in the same situation: 1 dose shortly before the RSV season starts.

If the mother received the RSV vaccine at least 14 days before delivery, nirsevimab is not usually needed.

Children aged 8–19 months at increased risk — including chronic lung disease of prematurity, severe immunocompromise, severe cystic fibrosis, and American Indian and Alaska Native children — get 1 dose before their second RSV season.

What happens at the vaccination visit

  • A single injection into the baby's thigh.
  • It can be given at the same visit as the routine childhood vaccines.

How to prepare

  • Tell the clinician whether you received the RSV vaccine (Abrysvo) during this pregnancy and when — it decides whether the antibody is needed.
  • Babies with a prolonged hospital stay after birth are usually immunised shortly before or promptly after discharge during the season.

What to expect afterwards

Soreness or a small rash at the injection site can occur; serious reactions are rare.

Protection lasts at least 5 months — covering a full RSV season.

Who should not get it, or should ask first

  • A baby who had a severe allergic reaction to nirsevimab or its components should not receive it again.
  • Babies who received nirsevimab should not also receive the older antibody palivizumab in the same season.
  • This product does not replace any routine childhood vaccine — the normal schedule continues unchanged.

Benefits

  • In studies, nirsevimab reduced RSV hospitalisations in infants by around three quarters or more.
  • One injection covers the whole first RSV season, including for premature babies.

Limits and possible harms

  • Reactions are uncommon and usually mild; severe allergy is rare.
  • Protection is temporary and teaches no lasting immunity — it is a shield for the highest-risk months, not a substitute for the immune system.

Useful links and tools

More in Flu, COVID-19 & Respiratory

Frequently asked questions

Why is this called an immunization but not a vaccine?

Because it works differently. A vaccine makes the body produce its own antibodies and memory cells. Nirsevimab supplies the antibody itself, made in a laboratory — protection is immediate but fades over about 5 months. CDC materials call both approaches 'immunization', and this guide labels the antibody honestly as a non-vaccine product.

My baby had the antibody — do they also need the pregnancy RSV vaccine route?

No. The two routes are alternatives: either the mother is vaccinated at 32–36 weeks in pregnancy (from the second pregnancy onwards, babies of mothers vaccinated in a previous pregnancy should get the antibody instead), or the baby receives nirsevimab. Most babies need only one of the two.

This guide explains how a vaccine is usually given and who it is generally offered to, following the CDC immunization schedules. It is general educational information only — not medical advice, and not a recommendation for you personally. Whether a vaccine is right for you depends on your age, health and history, so talk to your own clinician or pharmacist. If you are ill now, seek medical care promptly rather than waiting for a vaccination appointment.

← Flu, COVID-19 & Respiratory · Vaccines & Immunization home